CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that its scientists will present data from multiple research, pre-clinical, and clinical programs at the 4th annual meeting of the Oligonucleotide Therapeutics Society (OTS) being held October 15-18, 2008 at the Harvard Medical School in Boston, Massachusetts.
